IMTX is expected to report earnings to rise 168.36% to -29 cents per share on March 19
Q4'24
Est.
$-0.30
Q3'24
Beat
by $0.14
Q2'24
Beat
by $0.11
Q1'24
Beat
by $0.16
Q4'23
Beat
by $0.01
The last earnings report on November 18 showed earnings per share of -10 cents, beating the estimate of -25 cents. With 132.97K shares outstanding, the current market capitalization sits at 872.73M.
a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer